This article, featuring an infographic, details a head-to-head study comparing two neurokinin-1 receptor antagonists (fosnetupitant and fosaprepitant) for preventing chemotherapy-induced nausea and vomiting in patients with cancer.
The featured article was funded by Helsinn Healthcare.